Most Read Articles
Dr. Joseph Delano Fule Robles, 25 Oct 2016

Nivolumab did not meet the primary endpoint of superior progression-free survival (PFS) vs platinum-based chemotherapy in the phase III Checkmate026 trial in patients with stage IV recurrent, PD-L1–positive non-small-cell lung carcinoma (NSCLC), according to results reported recently at the European Society of Medical Oncology (ESMO) Congress 2016. 

Pearl Toh, 24 Nov 2016
New treatments such as pirfenidone and nintedanib slow lung function decline and progression of idiopathic pulmonary fibrosis (IPF), although response to treatment can vary dramatically among patients, according to a presentation at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) held in Bangkok, Thailand.
16 Oct 2016
Irritable bowel syndrome and asthma share a bidirectional association, a new study reports. Further, atopy potentially plays a role in the underlying mechanisms of this association.
Audrey Abella, 09 May 2018
The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with advanced, RET-altered solid cancers that progressed despite multikinase inhibitor therapy, according to data presented at AACR 2018.

4 phenotypic characteristics tied to slow gait speed in idiopathic pulmonary fibrosis

10 May 2018

Using the 4-metre gait speed (4MGS), a simple, reliable, valid and responsive tool, may help detect a patient with worse exercise performance, dyspnoea, health status and prognosis index in stable idiopathic fibrosis (IPF), suggests a study.

Intraclass correlation coefficients were 0.996 for interobserver and 0.983 for test–retest reliability. A robust association was observed between 4MGS and 6-min walking distance (6MWD; r, 0.76; p<0.0001), while moderate correlations existed with Medical Respiratory Council (MRC) dyspnoea score (r, –0.56), King’s Brief Interstitial Lung Disease (KBILD; r, 0.44) questionnaire, and Gender, Age and lung Physiology (GAP) prognostic index (r, –0.41; p<0.005 for all).

Pulmonary rehabilitation significantly improved 4MGS (mean change, 0.16 m/s; 95 percent CI, 0.12–0.20 m/s; effect size, 0.65). Despite similar lung function and high resolution computed tomography (HRCT) parameters, patients with slow vs preserved 4MGS had significantly worse exercise performance (6MWD, –167 m; –220 to –133 m), dyspnoea, health status and prognosis index.

The authors determined 4MGS interobserver (n=46) and test–retest (n=46) reliability, concurrent validity (n=65 and n=62) and responsiveness (n=60) in four prospective IPF cohorts. They also compared the phenotypic characteristics of all patients stratified according to slow 4MGS (<0.8 m/s), including lung function parameters, HRCT of the chest, 6MWD, MRC dyspnoea score, KBILD questionnaire and GAP prognostic index.

“Usual 4MGS is an established functional performance measure in older adults that consistently predicts adverse health outcomes, but few data exist in IPF,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 25 Oct 2016

Nivolumab did not meet the primary endpoint of superior progression-free survival (PFS) vs platinum-based chemotherapy in the phase III Checkmate026 trial in patients with stage IV recurrent, PD-L1–positive non-small-cell lung carcinoma (NSCLC), according to results reported recently at the European Society of Medical Oncology (ESMO) Congress 2016. 

Pearl Toh, 24 Nov 2016
New treatments such as pirfenidone and nintedanib slow lung function decline and progression of idiopathic pulmonary fibrosis (IPF), although response to treatment can vary dramatically among patients, according to a presentation at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) held in Bangkok, Thailand.
16 Oct 2016
Irritable bowel syndrome and asthma share a bidirectional association, a new study reports. Further, atopy potentially plays a role in the underlying mechanisms of this association.
Audrey Abella, 09 May 2018
The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with advanced, RET-altered solid cancers that progressed despite multikinase inhibitor therapy, according to data presented at AACR 2018.